Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

1.1K
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
1.1K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.4K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.4K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

1.3K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.3K
Positive Symptoms of Schizophrenia: Hallucinations and Delusions01:30

Positive Symptoms of Schizophrenia: Hallucinations and Delusions

1.0K
Schizophrenia is a complex mental health disorder that can manifest with various positive symptoms, including thought, movement, and behavior disorders. These symptoms significantly disrupt cognitive and motor functions, leading to profound effects on an individual's ability to engage with the world.
Thought Disorders
Disorganized and unusual thought processes mark thought disorders in schizophrenia. One key feature is disorganized speech, where an individual's conversation includes...
1.0K
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using the National Curriculum in Reproductive Psychiatry to Enhance and Standardize Fellowship Training.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2026
Same author

Regional, functional and transcriptomic decoding of multidimensional brain structure alterations in obsessive-compulsive disorder.

Nature communications·2026
Same author

Multimodal subspace independent vector analysis effectively captures latent relationships between brain structure and function.

Imaging neuroscience (Cambridge, Mass.)·2026
Same author

Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.

Neurology·2026
Same author

Decreased amyloid-related structure-function coupling in preclinical Alzheimer's disease.

Communications medicine·2026
Same author

An automated quantitative report for multiple sclerosis using only 3D T2-fluid-attenuated inversion recovery MRI.

Neuroradiology·2026
Same journal

Effects of family genetic risk scores and environmental factors on risk of schizophrenia and bipolar disorder.

Molecular psychiatry·2026
Same journal

Mitochondrial-inflammation crosstalk in major depressive disorder: molecular mechanisms and therapeutic implications.

Molecular psychiatry·2026
Same journal

Copy number variant scores are associated with cerebrovascular pathology in aging.

Molecular psychiatry·2026
Same journal

Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women.

Molecular psychiatry·2026
Same journal

Identification of hub genes involved in early-onset schizophrenia: from genetic susceptibility to predicted regulated gene expression.

Molecular psychiatry·2026
Same journal

Exercise-induced brain changes in cannabis use disorder: a longitudinal MRI study of a 12-week supervised HIIT program.

Molecular psychiatry·2026
See all related articles

Related Experiment Video

Updated: Mar 30, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.1K

Brain structural abnormalities in treatment-resistant schizophrenia.

Semra Etyemez1, Rohit Sivananthan1, Andreia V Faria2

  • 1Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Molecular Psychiatry
|March 28, 2026
PubMed
Summary
This summary is machine-generated.

Treatment-resistant schizophrenia (TRS) shows reduced hippocampus and superior frontal gyrus (SFG) volumes. These brain changes may serve as potential biomarkers for identifying TRS early, improving patient outcomes.

More Related Videos

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.9K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K

Related Experiment Videos

Last Updated: Mar 30, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.1K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.9K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Medical Imaging

Background:

  • Treatment-resistant schizophrenia (TRS) affects 10-60% of patients, lacking objective biomarkers for early intervention.
  • Previous studies suggest brain structural changes in TRS, but lack robust, large-scale data.
  • Timely intervention is crucial for improving clinical outcomes in TRS.

Purpose of the Study:

  • To investigate brain structural differences in treatment-resistant schizophrenia (TRS) using a meta- and mega-analysis approach.
  • To identify potential neuroimaging biomarkers for early detection of TRS.
  • To explore the relationship between antipsychotic exposure and brain structure in TRS.

Main Methods:

  • Collaborated with the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) consortium.
  • Conducted a meta- and mega-analysis of brain structural data from multiple international institutions.
  • Included healthy controls (HCs) and patients with non-TRS and TRS.

Main Results:

  • Found significantly reduced bilateral putamen and hippocampus volumes, and left superior frontal gyrus (SFG) surface area in TRS patients versus non-TRS patients.
  • Observed a decreasing trend in bilateral hippocampus volume and left SFG surface area from HCs to non-TRS to TRS patients.
  • Putamen volume increased in non-TRS patients compared to HCs, with antipsychotic exposure showing a small correlation.

Conclusions:

  • The hippocampus and SFG volume reductions are potential biomarkers for treatment-resistant schizophrenia (TRS).
  • These findings highlight the utility of large-scale neuroimaging meta-analyses for identifying biomarkers in complex psychiatric disorders.
  • Further research is warranted to validate these structural changes as reliable diagnostic tools for TRS.